Consumer health · Engineered probiotics
ZBiotics
The first genetically engineered probiotic ever sold to consumers, now past 15 million bottles and profitable. It reached the shelf as a food ingredient, on a safety pathway that involves no FDA review at all.
The vial on the desk
In 2019 a science reporter in Sydney opened a package mailed from San Francisco and found three small glass bottles. What made him hesitate was the contents. “The trillions of microbes inside the vial have never existed on Earth before.” A living organism no regulator anywhere had specifically approved had arrived by ordinary post.
He drank it. The bacteria, a strain of Bacillus subtilis called ZB183, carries one extra gene: an acetaldehyde dehydrogenase, the class of enzyme the liver uses to turn the toxic first breakdown product of alcohol into something harmless.
“We took a safe, edible bacteria that you eat every day, then engineered it to express an enzyme that is already in your body,” founder Zack Abbott told the San Francisco Chronicle in 2025. The company sells it as a shot you drink before the first round.
The problem it picked
Most alcohol goes to the liver, which handles both steps of the breakdown efficiently. A smaller share is metabolized in the gut, which is good at making acetaldehyde and poor at clearing it. Abbott has said colonic acetaldehyde runs five to ten times higher than blood levels, and that this pool is the target.
That gut acetaldehyde drives how you feel the next day is a hypothesis, not a finding. A 2020 review in the Journal of Clinical Medicine, cited by the Chronicle, concluded that “only a few studies have reported correlations between hangover severity and acetaldehyde concentrations.” Hangovers also involve dehydration, disturbed sleep, inflammation and gastrointestinal irritation, none of which ZB183 touches.
The company is careful about this, and has been from the start. It does not use the phrase hangover cure. Its FAQ states plainly that FDA compliance is not FDA approval. Its label carries the standard line that the statements have not been evaluated by the Food and Drug Administration.
A microbiologist and a law student
Abbott studied molecular and cell biology at Berkeley, bartended, played rugby for a US team at the Maccabi Games, then came back to science through an HIV lab at UC Davis. He earned a PhD in microbiology and immunology at Michigan in 2015 under Michele Swanson, a past president of the American Society for Microbiology.
His idea was an inversion: rather than manufacture and purify an enzyme, sell the organism that makes it. “Instead of giving you the protein, I could give you the protein factory,” he told AgFunderNews. Spores are shelf stable, survive stomach acid, and germinate in the intestine, where they keep producing.
He rented lab space in Berkeley in 2016 and, by the company's account, slept on the floor beside the bench to keep experiments running. In May 2017 he brought in Stephen Lamb, then finishing a joint JD and MBA at Penn. They joined Y Combinator in January 2018, ran an Indiegogo campaign that August, and launched Pre-Alcohol in August 2019.
From a car full of samples to Total Wine
Early distribution was two founders driving down the 101 hand delivering vials. Direct to consumer came first, Amazon in 2023, then shelves. By July 2026 the company said it was selling through Total Wine, Bevmo, specialty grocery chains and restaurants, and had passed 15 million bottles.
A second product arrived in September 2024. Sugar-to-Fiber uses strain ZB423, engineered to express levansucrase, which splits sucrose and stacks the freed fructose into levan, a prebiotic fiber. Abbott puts the conversion at roughly 5 to 10 grams of sugar per day. In 2026 the company said it had acquired prebiotic, probiotic and polyphenol assets from January AI.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| FDA premarket review | None. Both products are foods, not drugs and not dietary supplements. The company states it met new ingredient requirements “through self-certification of Generally Recognized as Safe” status under 21 CFR 170.3 and 170.30. Self-affirmation requires no notice to FDA and no agency response. | Company-stated |
| GRAS notice inventory | Two attorneys writing in FDLI Update in April 2026 checked the FDA GRAS notice database on Feb 2, 2026 and found neither ZB183 nor ZB423 in it. In July 2026 the company said full FDA submissions were in the pipeline. None had appeared by Sep 22, 2026. | Independent |
| Animal safety, ZB183 | 90-day repeat dose oral gavage study in Wistar rats, Journal of Toxicology, 2019, PMID 31781202, with ZBiotics staff as co-authors. The company reports a no observed adverse effect level near 1011 CFU per kg per day. | Public record |
| Animal safety, ZB423 | Matching 90-day gavage study in Wistar rats, Journal of Applied Toxicology, December 2024, PMID 39168852. ZBiotics staff again co-authors. | Public record |
| Strain engineering | PLoS One, 2024, PMID 39509360, on hag locus integration to express acetaldehyde dehydrogenase robustly. All five authors are ZBiotics staff. A construction paper, not an efficacy paper. | Public record |
| Human efficacy | No registered trial and no published human study for either strain. The company cites internal work: a blinded placebo comparison it ran itself, and 94 percent of participants reporting they felt better. Neither has been published or reviewed outside the company. | Not found |
| Independent research | An Egyptian academic group used the commercial ZB183 product in a rat model of non-alcoholic steatohepatitis and reported less hepatic inflammation, RSC Medicinal Chemistry, 2024. Rats, and not about drinking. | Public record |
| Federal support | No NIH or NSF awards, no FDA 510(k) or PMA records, and no registered trials in the records pulled for this profile. | Not found |
| Commercial scale | 15 million bottles sold by July 2026, the 10 millionth in November 2025, profitable since 2023, compound annual growth near 113 percent from 2021 through 2025. All company-reported, none audited. | Company-stated |
Read plainly: the safety file is real and the chemistry is real. ZB183 makes the enzyme, and the enzyme destroys acetaldehyde in a tube and in gut-simulated conditions. What has never been tested in a controlled human trial is the link the product is bought for, that clearing gut acetaldehyde changes how a person feels the next morning. The company points to repurchase rates instead. That is a commercial answer to a scientific question, and it is the whole argument.
What to watch
- Whether the promised FDA GRAS notices for ZB183 and ZB423 are filed, and whether the agency returns no questions letters.
- Any published human study. The company said in 2025 it wanted to run publishable human trials on Sugar-to-Fiber.
- Rulemaking on self-affirmed GRAS. HHS directed FDA to explore closing the pathway in March 2025.
- Whether a third product ships, and whether the January AI assets turn into one.
- Whether any competitor follows. Seven years after launch, ZBiotics says none has.
In their words
“This is not your ‘get-out-of-jail-free card’ hangover cure because that doesn’t exist”
Zack Abbott, co-founder and CEO, to CNET, 2019 · Independent
“This is science and not science fiction.”
Zack Abbott, to CNET, 2019 · Independent
“I certainly wouldn’t classify us as a probiotics company”
Zack Abbott, to CNET, 2019 · Independent
“We’re self-GRAS (generally recognized as safe), which required a 90-day rodent study, that showed no toxicity”
Zack Abbott, to AgFunderNews, 2023 · Interview
“I’d love to have the budget to launch full clinical trials and demonstrate efficacy”
John W. Oliver, head of R&D, to Chemical and Engineering News, 2019, quoted by the Atlanta Journal-Constitution · Independent
“The gold standard of effectiveness is the controlled, double-blind clinical trial”
Dr. Robert Swift, Brown University, on hangover products generally, TIME, 2025 · Independent
“ZBiotics appears to have used the GRAS self-affirmation process for both products, based on their absence from the FDA’s online database of GRAS notification filings.”
Benjamin Snitkoff and Frank S. David, FDLI Update, 2026 · Legal analysis
“Our compound annual growth rate from 2021 through 2025 was approximately 113%.”
Zack Abbott, to AgFunderNews, 2026 · Company-stated
Related companies
Sources
- Public recordForm D, ZBiotics Co, CIK 0001807168
- Public recordForm D, Zbiotics Co, CIK 0001807168
- Public recordLyophilized B. subtilis ZB183 Spores: 90-Day Repeat Dose Oral (Gavage) Toxicity Study in Wistar Rats
- Public recordBacillus subtilis ZB423: 90-Day repeat dose oral (gavage) toxicity study in Wistar rats
- Public recordEngineering a probiotic Bacillus subtilis for acetaldehyde removal
- Public recordGenetically engineered probiotic Zbiotics (ZB183) for NASH management via the cGAS-STING pathway
- Legal analysisThe Need for Stronger Regulation of Engineered Live Microbes as Foods
- IndependentThis Bay Area-made hangover cure has sold 10 million bottles. But does it work?
- IndependentZBiotics takes GM probiotics mainstream with 15m+ pre-alcohol shots sold
- InterviewDesigner probiotics startup ZBiotics has sold 8 million pre-alcohol shots
- InterviewMeet the founder: ZBiotics Zack Abbott on designer probiotics
- IndependentPoo transplants and hangover cures: Inside the murky world of probiotics
- IndependentDo Hangover Prevention Supplements Really Work?
- IndependentDrink genetically engineered to eliminate rough mornings after drinking
- CompanyZBiotics Raises $12M Series A
- CompanyZBiotics Launches Sugar-to-Fiber Probiotic Drink Mix
- CompanyIs ZBiotics Safe? 4+ Years of Testing Our Enhanced Probiotic Drink
- CompanyZBiotics FAQ, founding story and How It Works pages
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
